Upadacitinib Superior to Placebo in Moderate-to-Severe Crohn Disease

WEDNESDAY, May 31, 2023 -- For patients with moderate-to-severe Crohn disease, upadacitinib induction and maintenance treatment are superior to placebo, according to a study published in the May 25 issue of the New England Journal of...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news